Literature DB >> 21685934

TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling.

A Fiorio Pla1, H L Ong, K T Cheng, A Brossa, B Bussolati, T Lockwich, B Paria, L Munaron, I S Ambudkar.   

Abstract

Changes in intracellular calcium [Ca(2+)](i) levels control critical cytosolic and nuclear events that are involved in the initiation and progression of tumor angiogenesis in endothelial cells (ECs). Therefore, the mechanism(s) involved in agonist-induced Ca(2+)(i) signaling is a potentially important molecular target for controlling angiogenesis and tumor growth. Several studies have shown that blood vessels in tumors differ from normal vessels in their morphology, blood flow and permeability. We had previously reported a key role for arachidonic acid (AA)-mediated Ca(2+) entry in the initial stages of tumor angiogenesis in vitro. In this study we assessed the mechanism involved in AA-induced EC migration. We report that TRPV4, an AA-activated channel, is differentially expressed in EC derived from human breast carcinomas (BTEC) as compared with 'normal' EC (HMVEC). BTEC display a significant increase in TRPV4 expression, which was correlated with greater Ca(2+) entry, induced by AA or 4αPDD (a selective TRPV4 agonist) in the tumor-derived ECs. Wound-healing assays revealed a key role of TRPV4 in regulating cell migration of BTEC but not HMVEC. Knockdown of TRPV4 expression completely abolished AA-induced BTEC migration, suggesting that TRPV4 mediates the pro-angiogenic effects promoted by AA. Furthermore, pre-incubation of BTEC with AA induced actin remodeling and a subsequent increase in the surface expression of TRPV4. This was consistent with the increased plasma membrane localization of TRPV4 and higher AA-stimulated Ca(2+) entry in the migrating cells. Together, the data presented herein demonstrate that: (1) TRPV4 is differentially expressed in tumor-derived versus 'normal' EC; (2) TRPV4 has a critical role in the migration of tumor-derived but not 'normal' EC migration; and (3) AA induces actin remodeling in BTEC, resulting in a corresponding increase of TRPV4 expression in the plasma membrane. We suggest that the latter is critical for migration of EC and thus in promoting angiogenesis and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685934      PMCID: PMC5934994          DOI: 10.1038/onc.2011.231

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  Temperature-modulated diversity of TRPV4 channel gating: activation by physical stresses and phorbol ester derivatives through protein kinase C-dependent and -independent pathways.

Authors:  Xiaochong Gao; Ling Wu; Roger G O'Neil
Journal:  J Biol Chem       Date:  2003-05-08       Impact factor: 5.157

2.  Arachidonic acid induces the activation of the stress-activated protein kinase, membrane ruffling and H2O2 production via a small GTPase Rac1.

Authors:  E A Shin; K H Kim; S I Han; K S Ha; J H Kim; K I Kang; H D Kim; H S Kang
Journal:  FEBS Lett       Date:  1999-06-11       Impact factor: 4.124

3.  A novel function of capsaicin-sensitive TRPV1 channels: involvement in cell migration.

Authors:  J Waning; J Vriens; G Owsianik; L Stüwe; S Mally; A Fabian; C Frippiat; B Nilius; A Schwab
Journal:  Cell Calcium       Date:  2006-12-20       Impact factor: 6.817

Review 4.  Tumor exploits alternative strategies to achieve vascularization.

Authors:  Benedetta Bussolati; Cristina Grange; Giovanni Camussi
Journal:  FASEB J       Date:  2011-05-31       Impact factor: 5.191

Review 5.  Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis.

Authors:  C A C Hyde; S Missailidis
Journal:  Int Immunopharmacol       Date:  2009-02-23       Impact factor: 4.932

6.  Evidence of a role for TRPC channels in VEGF-mediated increased vascular permeability in vivo.

Authors:  T M Pocock; R R Foster; D O Bates
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-10-09       Impact factor: 4.733

7.  TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling.

Authors:  Charles K Thodeti; Benjamin Matthews; Arvind Ravi; Akiko Mammoto; Kaustabh Ghosh; Abigail L Bracha; Donald E Ingber
Journal:  Circ Res       Date:  2009-04-09       Impact factor: 17.367

8.  Arachidonic acid-induced Ca2+ entry is involved in early steps of tumor angiogenesis.

Authors:  Alessandra Fiorio Pla; Cristina Grange; Susanna Antoniotti; Cristiana Tomatis; Annalisa Merlino; Benedetta Bussolati; Luca Munaron
Journal:  Mol Cancer Res       Date:  2008-04       Impact factor: 5.852

9.  Trpv4 induces collateral vessel growth during regeneration of the arterial circulation.

Authors:  Christian Troidl; Kerstin Troidl; Wilma Schierling; Wei-Jun Cai; Holger Nef; Helge Möllmann; Sava Kostin; Sylvia Schimanski; Linda Hammer; Albrecht Elsässer; Thomas Schmitz-Rixen; Wolfgang Schaper
Journal:  J Cell Mol Med       Date:  2009-02-06       Impact factor: 5.310

10.  Sensitization and translocation of TRPV1 by insulin and IGF-I.

Authors:  Jeremy J Van Buren; Satyanarayan Bhat; Rebecca Rotello; Mary E Pauza; Louis S Premkumar
Journal:  Mol Pain       Date:  2005-04-27       Impact factor: 3.395

View more
  64 in total

1.  Human cytomegalovirus US21 protein is a viroporin that modulates calcium homeostasis and protects cells against apoptosis.

Authors:  Anna Luganini; Giovanna Di Nardo; Luca Munaron; Gianfranco Gilardi; Alessandra Fiorio Pla; Giorgio Gribaudo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

2.  TRPV4 participates in the establishment of trailing adhesions and directional persistence of migrating cells.

Authors:  Sanela Mrkonjić; Anna Garcia-Elias; Carlos Pardo-Pastor; Elsa Bazellières; Xavier Trepat; Joris Vriens; Debapriya Ghosh; Thomas Voets; Rubén Vicente; Miguel A Valverde
Journal:  Pflugers Arch       Date:  2015-01-06       Impact factor: 3.657

Review 3.  Transient receptor potential channels in the vasculature.

Authors:  Scott Earley; Joseph E Brayden
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 4.  Transient Receptor Potential Channels and Endothelial Cell Calcium Signaling.

Authors:  Pratish Thakore; Scott Earley
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 5.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 6.  Calcium channels and pumps in cancer: changes and consequences.

Authors:  Gregory R Monteith; Felicity M Davis; Sarah J Roberts-Thomson
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

Review 7.  Calcium influx pathways in breast cancer: opportunities for pharmacological intervention.

Authors:  I Azimi; S J Roberts-Thomson; G R Monteith
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Update on vascular endothelial Ca(2+) signalling: A tale of ion channels, pumps and transporters.

Authors:  Francesco Moccia; Roberto Berra-Romani; Franco Tanzi
Journal:  World J Biol Chem       Date:  2012-07-26

9.  Shear stress mediates exocytosis of functional TRPV4 channels in endothelial cells.

Authors:  Sara Baratchi; Juhura G Almazi; William Darby; Francisco J Tovar-Lopez; Arnan Mitchell; Peter McIntyre
Journal:  Cell Mol Life Sci       Date:  2015-08-20       Impact factor: 9.261

10.  Recurrent de novo mutations in PACS1 cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome.

Authors:  Janneke H M Schuurs-Hoeijmakers; Edwin C Oh; Lisenka E L M Vissers; Mariëlle E M Swinkels; Christian Gilissen; Michèl A Willemsen; Maureen Holvoet; Marloes Steehouwer; Joris A Veltman; Bert B A de Vries; Hans van Bokhoven; Arjan P M de Brouwer; Nicholas Katsanis; Koenraad Devriendt; Han G Brunner
Journal:  Am J Hum Genet       Date:  2012-11-15       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.